{"schemaVersion":"peptidescanner-evidence-bundle/v1","canonicalUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json","manifestUrl":"https://peptidescanner.com/evidence/v1/manifest.json","peptide":{"slug":"motixafortide","name":"Motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"},"addressing":"objects is keyed by objectPathId. A URL fragment #<objectPathId> on this file names one evidence object. Every version of a record is placed in the bundle of the record's current first peptide.","objectCount":17,"objects":{"clinicaltrials-gov-nct04543071-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct04543071-motixafortide:v1","objectPathId":"clinicaltrials-gov-nct04543071-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04543071-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct04543071-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct04543071-motixafortide-v1"},"story":{"slug":"clinicaltrials-gov-nct04543071-motixafortide","version":1,"domain":"Clinical trials","dateInSource":"2026-09-21","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT04543071","sourceIds":["ctg-observation-nct04543071-2026-09-21-7862f0a88bf1"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct04543071-2026-09-21-7862f0a88bf1"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT04543071 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-21, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct04543071-2026-09-21-7862f0a88bf1"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct04543071-2026-09-21-7862f0a88bf1"]}],"sources":[{"id":"ctg-observation-nct04543071-2026-09-21-7862f0a88bf1","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT04543071 · retained source version 2026-09-21:7862f0a88bf1caf6146bcf84754fc641d45d1a2f3a281dd72e12c7d3e15f6b6d","url":"https://clinicaltrials.gov/study/NCT04543071"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"267bb133ad7f44837589e4cf6cd66ac4395a44bd7395a5b85b12179e924b1d0a","tierARecordSha256":"402e97ebc5867c61cd9c635f1725f7b8953f572ffde239e5aa858bafc1e587e3"},"integrity":{"algorithm":"sha256","contentSha256":"217ead00a2cbc4bbc1031217a72bbf1c3614df3c117d007df05488efac3da0b8"}},"clinicaltrials-gov-nct05618301-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct05618301-motixafortide:v1","objectPathId":"clinicaltrials-gov-nct05618301-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct05618301-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct05618301-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct05618301-motixafortide-v1"},"story":{"slug":"clinicaltrials-gov-nct05618301-motixafortide","version":1,"domain":"Clinical trials","dateInSource":"2025-08-11","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT05618301","sourceIds":["ctg-observation-nct05618301-2025-08-11-46d2cca30b6b"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct05618301-2025-08-11-46d2cca30b6b"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT05618301 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-11, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct05618301-2025-08-11-46d2cca30b6b"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct05618301-2025-08-11-46d2cca30b6b"]}],"sources":[{"id":"ctg-observation-nct05618301-2025-08-11-46d2cca30b6b","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT05618301 · retained source version 2025-08-11:46d2cca30b6b5a9c00327a8d79058b0641eac735c13ec25cf2298d0b11ed98c2","url":"https://clinicaltrials.gov/study/NCT05618301"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"5cd90018ecd8ebd839ed8ec3dd07dcf29cf9a8a7b1113939ee12926a6585a151","tierARecordSha256":"ff6e05593bc8de3a68463a076e2df9eba0aa0a7068c25b855aaeb024eb14b597"},"integrity":{"algorithm":"sha256","contentSha256":"5a5c9429767f6f10283d08f3da027d5150bb03a084df2be24274dec635d98a64"}},"clinicaltrials-gov-nct06442761-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct06442761-motixafortide:v1","objectPathId":"clinicaltrials-gov-nct06442761-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct06442761-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06442761-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct06442761-motixafortide-v1"},"story":{"slug":"clinicaltrials-gov-nct06442761-motixafortide","version":1,"domain":"Clinical trials","dateInSource":"2026-09-08","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT06442761","sourceIds":["ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT06442761 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6"]}],"sources":[{"id":"ctg-observation-nct06442761-2026-09-08-d1dd4c1ff4d6","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT06442761 · retained source version 2026-09-08:d1dd4c1ff4d6a2c74426844240bd467d997ea6efa22020dd266b584be851b9cb","url":"https://clinicaltrials.gov/study/NCT06442761"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"20479502a3fc1a4be92897df34ded0df0cb10e7c73b0c7405820c4787610bf2a","tierARecordSha256":"68a536c36ed6da3c9bd972160862c3e7be87fee99bf3fbbf762c1f3150721e8c"},"integrity":{"algorithm":"sha256","contentSha256":"fd80f201528c172bcfd6710d5d137710c86d1f63a0c7b865b1f0bc0f6f92e87b"}},"clinicaltrials-gov-nct06506461-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct06506461-motixafortide:v1","objectPathId":"clinicaltrials-gov-nct06506461-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct06506461-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06506461-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct06506461-motixafortide-v1"},"story":{"slug":"clinicaltrials-gov-nct06506461-motixafortide","version":1,"domain":"Clinical trials","dateInSource":"2026-10-15","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT06506461","sourceIds":["ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT06506461 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2"]}],"sources":[{"id":"ctg-observation-nct06506461-2026-10-15-a31b8b04e5e2","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT06506461 · retained source version 2026-10-15:a31b8b04e5e2490afe251c9eddd6ca4d1e17ff3c75786e3c5ab1525f636e0cee","url":"https://clinicaltrials.gov/study/NCT06506461"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"ad0258dd27d585c4d2caad20809546802b20441d444aa103c29386c6aa6150d9","tierARecordSha256":"8b18eddba49430a3d86a84d00c646c3eb299b776587ebe6fe970522491e94bdd"},"integrity":{"algorithm":"sha256","contentSha256":"1f6d378479f407ebe35ca942c96612c0fdc9ed2abfd9020bc02f7e80d8a99277"}},"clinicaltrials-gov-nct06547112-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct06547112-motixafortide:v1","objectPathId":"clinicaltrials-gov-nct06547112-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct06547112-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06547112-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct06547112-motixafortide-v1"},"story":{"slug":"clinicaltrials-gov-nct06547112-motixafortide","version":1,"domain":"Clinical trials","dateInSource":"2025-08-29","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT06547112","sourceIds":["ctg-observation-nct06547112-2025-08-29-4ed42583441f"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct06547112-2025-08-29-4ed42583441f"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT06547112 at 2026-11-16T01:39:10.285Z. Its registry update date was 2025-08-29, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct06547112-2025-08-29-4ed42583441f"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct06547112-2025-08-29-4ed42583441f"]}],"sources":[{"id":"ctg-observation-nct06547112-2025-08-29-4ed42583441f","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT06547112 · retained source version 2025-08-29:4ed42583441f2698fd97f5863ef39be495f089bf14d2ebd9b68449fb31e401af","url":"https://clinicaltrials.gov/study/NCT06547112"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"e16a424013f6ebda42c1e010386e5ca4ffcd0ac21dbd48410c2fdc05e4107c54","tierARecordSha256":"ffe67727b241b646fe83e0c69cab8aba9dbffce6e5721c1eeac76dad359e0d6e"},"integrity":{"algorithm":"sha256","contentSha256":"0d5dd7ddd36ffd4d0836bf7ee82e2926b5fa4fc73777851f10b369702a396e34"}},"clinicaltrials-gov-nct07101445-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct07101445-motixafortide:v1","objectPathId":"clinicaltrials-gov-nct07101445-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct07101445-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07101445-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct07101445-motixafortide-v1"},"story":{"slug":"clinicaltrials-gov-nct07101445-motixafortide","version":1,"domain":"Clinical trials","dateInSource":"2026-07-23","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT07101445","sourceIds":["ctg-observation-nct07101445-2026-07-23-1ae1329888f7"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct07101445-2026-07-23-1ae1329888f7"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT07101445 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-23, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct07101445-2026-07-23-1ae1329888f7"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct07101445-2026-07-23-1ae1329888f7"]}],"sources":[{"id":"ctg-observation-nct07101445-2026-07-23-1ae1329888f7","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07101445 · retained source version 2026-07-23:1ae1329888f72decdc1d2285059622e40088d98969222424c8ebe99668e9b7fe","url":"https://clinicaltrials.gov/study/NCT07101445"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7e179d91fd82c23d84895569bf753399cc8b23c19d9020e6e58cb1a0c722965b","tierARecordSha256":"43f822443d78a6dc3026a58a4331974a8fafefa5414acb4e96b813ea87061b05"},"integrity":{"algorithm":"sha256","contentSha256":"11e820fff698897018694eee1b8736b1f1ed51674e67a9753ab4c27687344adf"}},"clinicaltrials-gov-nct07392970-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct07392970-motixafortide:v1","objectPathId":"clinicaltrials-gov-nct07392970-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct07392970-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07392970-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct07392970-motixafortide-v1"},"story":{"slug":"clinicaltrials-gov-nct07392970-motixafortide","version":1,"domain":"Clinical trials","dateInSource":"2026-07-24","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT07392970","sourceIds":["ctg-observation-nct07392970-2026-07-24-fee94029badb"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct07392970-2026-07-24-fee94029badb"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.","sourceIds":["ctg-observation-nct07392970-2026-07-24-fee94029badb"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct07392970-2026-07-24-fee94029badb"]}],"sources":[{"id":"ctg-observation-nct07392970-2026-07-24-fee94029badb","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07392970 · retained source version 2026-07-24:fee94029badb26594534c702c6c4ea1df6e065cec1e928fcbc5375e29ec6076a","url":"https://clinicaltrials.gov/study/NCT07392970"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"b4d4453fd9a91ed32d57124a0022d7a4ecfebfc8f968c62137bfa4e358f81624","tierARecordSha256":"05c330ed98785d6e8c0a9f648b598a8075791e943e3fad13c1f49c4ab4bb9d6a"},"integrity":{"algorithm":"sha256","contentSha256":"0b0dfd93d2abb8140450502fccb5892ebe93b65ec23f3e910063e97343eac709"}},"fda-drugs-nda217159-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:fda-drugs-nda217159:v1","objectPathId":"fda-drugs-nda217159-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/fda-drugs-nda217159/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#fda-drugs-nda217159-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#fda-drugs-nda217159-v1"},"story":{"slug":"fda-drugs-nda217159","version":1,"domain":"Regulatory","dateInSource":"2023-09-08","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Drugs@FDA application NDA217159","sourceIds":["fda-drugs-nda217159-2023-09-08-b15bf44a56da"]},{"id":"summary","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients.","sourceIds":["fda-drugs-nda217159-2023-09-08-b15bf44a56da"]},{"id":"paragraph-1","text":"The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients.","sourceIds":["fda-drugs-nda217159-2023-09-08-b15bf44a56da"]},{"id":"paragraph-2","text":"This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance.","sourceIds":["fda-drugs-nda217159-2023-09-08-b15bf44a56da"]}],"sources":[{"id":"fda-drugs-nda217159-2023-09-08-b15bf44a56da","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA217159 · original submission status AP · 2023-09-08 · dataset 2026-11-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217159%22&limit=1"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"f5520629c2894a8839d8a9b1c709f2820eaa72c76b2475f4ff950f2465ed1850","tierARecordSha256":"b15bf44a56da92933367f0e3473dcd67ca2788271adc37197081e828c4ce077f"},"integrity":{"algorithm":"sha256","contentSha256":"fcebc83bfc1bd1a00625b0fcc9b7824923afbe0666fd0502b33f27476f821052"}},"pubmed-pmid-34253578-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-34253578-motixafortide:v1","objectPathId":"pubmed-pmid-34253578-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-34253578-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-34253578-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-34253578-motixafortide-v1"},"story":{"slug":"pubmed-pmid-34253578-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2022-04-01","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.","sourceIds":["pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db"]},{"id":"summary","text":"PubMed lists PMID 34253578 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-07-12 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db"]},{"id":"paragraph-1","text":"PubMed lists PMID 34253578 in Clinical cancer research : an official journal of the American Association for Cancer Research as Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-07-12 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db"]}],"sources":[{"id":"pubmed-observation-pmid-34253578-2022-04-01-1ac8436395db","name":"PubMed","sourceClass":"A","title":"Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. · retained source version 1:2022-04-01:current:1ac8436395db8f72e98b5c1b8f1bcbacfddd4c9bed28fa7db6a74c5286345267","url":"https://pubmed.ncbi.nlm.nih.gov/34253578/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"68385eba01bc3ddea2d55b3f1164e67762b30bf526bce1ada791ae1da9d229ff","tierARecordSha256":"8ad784be2a3dea6e8c8cb3d04eaa73a2b97f022893ce913e86930e552a1d9787"},"integrity":{"algorithm":"sha256","contentSha256":"6d0b3b75df5b52b4f8eca71c2cd6706c438eaa534e73ffafb19c3e2343eabb68"}},"pubmed-pmid-36901829-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-36901829-motixafortide:v1","objectPathId":"pubmed-pmid-36901829-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-36901829-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-36901829-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-36901829-motixafortide-v1"},"story":{"slug":"pubmed-pmid-36901829-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2023-03-14","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.","sourceIds":["pubmed-observation-pmid-36901829-2023-03-14-7816465e168a"]},{"id":"summary","text":"PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-36901829-2023-03-14-7816465e168a"]},{"id":"paragraph-1","text":"PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-36901829-2023-03-14-7816465e168a"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-36901829-2023-03-14-7816465e168a"]}],"sources":[{"id":"pubmed-observation-pmid-36901829-2023-03-14-7816465e168a","name":"PubMed","sourceClass":"A","title":"Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor. · retained source version 1:2023-03-14:current:7816465e168a63a7f42c0d34cc30f50553a64def31e14466517c43c97fdd2670","url":"https://pubmed.ncbi.nlm.nih.gov/36901829/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"3329509785806f82fcccd43488f26cd7cf0dd0500954becaf0317919e2d81329","tierARecordSha256":"aac1eaca2eb649fe84debdc1b4533e17028bff9ae8aa99e3397a192e95fc146a"},"integrity":{"algorithm":"sha256","contentSha256":"2e305d07d1ca4b5d1fbd6ab054156352894ee7af58d3ff5586a5d0cdbef2f63a"}},"pubmed-pmid-37069359-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-37069359-motixafortide:v1","objectPathId":"pubmed-pmid-37069359-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-37069359-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37069359-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-37069359-motixafortide-v1"},"story":{"slug":"pubmed-pmid-37069359-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2026-11-09","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.","sourceIds":["pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281"]},{"id":"summary","text":"PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281"]},{"id":"paragraph-1","text":"PubMed lists PMID 37069359 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281"]}],"sources":[{"id":"pubmed-observation-pmid-37069359-2026-11-09-23b1564a2281","name":"PubMed","sourceClass":"A","title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. · retained source version 1:2026-11-09:current:23b1564a2281305c6474597b6225a7f34d307ed0928a167a60175043c2bbef17","url":"https://pubmed.ncbi.nlm.nih.gov/37069359/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d43d858973865a9f41dfd24a38eebae600b83065a6c9756c76368a3d2bd86939","tierARecordSha256":"0b9d92b91151810c5d511f55a8e6ce05ada5ceb48998ec511e2221860c791b17"},"integrity":{"algorithm":"sha256","contentSha256":"499a69353d02f88edc61d315066308670719df2daf837c69031cfe415104f6b2"}},"pubmed-pmid-37862457-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-37862457-motixafortide:v1","objectPathId":"pubmed-pmid-37862457-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-37862457-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37862457-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-37862457-motixafortide-v1"},"story":{"slug":"pubmed-pmid-37862457-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2024-10-09","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Motixafortide Acetate.","sourceIds":["pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430"]},{"id":"summary","text":"PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430"]},{"id":"paragraph-1","text":"PubMed lists PMID 37862457 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2024-01-01 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430"]}],"sources":[{"id":"pubmed-observation-pmid-37862457-2024-10-09-5a3c0499d430","name":"PubMed","sourceClass":"A","title":"Motixafortide Acetate. · retained source version 1:2024-10-09:current:5a3c0499d430aadf43d28638c4786feaff5a89fcb1b76d5f1a31fdbc68143ba0","url":"https://pubmed.ncbi.nlm.nih.gov/37862457/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"b29c69f11e59a9a8628c89075ed5e6ed7ac4ab5c4db1642cf34f5c118fe479f7","tierARecordSha256":"1fcc5c5840c311321260889f98627bdf3edd68fa57a3f8f4e36c3711b1b0b85e"},"integrity":{"algorithm":"sha256","contentSha256":"e8947914519395f8c74209bfc9e4a69393ea41a6c28bc127018863b53e17e4d3"}},"pubmed-pmid-38629183-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38629183-motixafortide:v1","objectPathId":"pubmed-pmid-38629183-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38629183-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-38629183-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-38629183-motixafortide-v1"},"story":{"slug":"pubmed-pmid-38629183-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2024-10-30","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.","sourceIds":["pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52"]},{"id":"summary","text":"PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52"]},{"id":"paragraph-1","text":"PubMed lists PMID 38629183 in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners as Journal Article, Comparative Study, Review, with publication-date metadata of 2024-04-17 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52"]}],"sources":[{"id":"pubmed-observation-pmid-38629183-2024-10-30-241b7d23cf52","name":"PubMed","sourceClass":"A","title":"A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection. · retained source version 1:2024-10-30:current:241b7d23cf528c17a5001110748a18b2737cf5fd5c56132f013aca51316f1e7f","url":"https://pubmed.ncbi.nlm.nih.gov/38629183/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"aee4a743987fe9ac47df5172e8916d7879ab38cbeb1daf2d3c9bb05b941ed4c9","tierARecordSha256":"a964b61846d81e6833886436eae34b49d4b9803324111668fc92e5d1d0646e23"},"integrity":{"algorithm":"sha256","contentSha256":"d931bc99ffc9065a01e5c125e088c8469c217e8937b397d215276efe9afd87cb"}},"pubmed-pmid-40420423-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-40420423-motixafortide:v1","objectPathId":"pubmed-pmid-40420423-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-40420423-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-40420423-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-40420423-motixafortide-v1"},"story":{"slug":"pubmed-pmid-40420423-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2025-05-27","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma.","sourceIds":["pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d"]},{"id":"summary","text":"PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d"]},{"id":"paragraph-1","text":"PubMed lists PMID 40420423 in Biomedical chromatography : BMC as Journal Article, with publication-date metadata of 2025-07 (month precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d"]}],"sources":[{"id":"pubmed-observation-pmid-40420423-2025-05-27-65cc5143fe7d","name":"PubMed","sourceClass":"A","title":"Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma. · retained source version 1:2025-05-27:current:65cc5143fe7da8368ee98228cb06ef9e226278692af862b31d737555f95588e8","url":"https://pubmed.ncbi.nlm.nih.gov/40420423/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d80eed2c077f7cdf70c71d318a4b8845bc9a345f556e2cd26e9aabc81183c72e","tierARecordSha256":"462e9dab3bd9a99ab24ed4bf6e9e39f10b48db882f4a877cbc9e1504bd5bc80c"},"integrity":{"algorithm":"sha256","contentSha256":"12c915f001bcba800bc08cd4bfd9c7c66a353067b2828c8400f4446d4fe16597"}},"pubmed-pmid-41741368-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-41741368-motixafortide:v1","objectPathId":"pubmed-pmid-41741368-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-41741368-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-41741368-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-41741368-motixafortide-v1"},"story":{"slug":"pubmed-pmid-41741368-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2026-08-13","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.","sourceIds":["pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c"]},{"id":"summary","text":"PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c"]},{"id":"paragraph-1","text":"PubMed lists PMID 41741368 in The oncologist as Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-09 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c"]}],"sources":[{"id":"pubmed-observation-pmid-41741368-2026-08-13-3dca2b03912c","name":"PubMed","sourceClass":"A","title":"Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. · retained source version 1:2026-08-13:current:3dca2b03912c56d85d44d318a88dbd4a4a2560315f1925a4585084912e8abeb3","url":"https://pubmed.ncbi.nlm.nih.gov/41741368/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"a5ed0515bd40775c54197cb79b4131be701223d204551b965d30ae324ba3baa2","tierARecordSha256":"1d0cad74c1eb5f31bec46e6b1a5be381237d826ceb58e7a8650d3b7ff2124278"},"integrity":{"algorithm":"sha256","contentSha256":"b15bc82980fb1284ba9fda2e53207d2e3e7382fa9e4f21a79a9931871e515ea6"}},"pubmed-pmid-42435378-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42435378-motixafortide:v1","objectPathId":"pubmed-pmid-42435378-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42435378-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42435378-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-42435378-motixafortide-v1"},"story":{"slug":"pubmed-pmid-42435378-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2026-07-11","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience.","sourceIds":["pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10"]},{"id":"summary","text":"PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10"]},{"id":"paragraph-1","text":"PubMed lists PMID 42435378 in Transfusion as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10"]}],"sources":[{"id":"pubmed-observation-pmid-42435378-2026-07-11-1a6503110c10","name":"PubMed","sourceClass":"A","title":"Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience. · retained source version 1:2026-07-11:current:1a6503110c10dd65b42f3d8f7ed3cab407b94dd5169fec82ecbb7fcffd0ce85c","url":"https://pubmed.ncbi.nlm.nih.gov/42435378/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"94393264233ba7d8889d004a36ecdd88f7e735a40b36dc24edc470f84d1dd241","tierARecordSha256":"90b9e83f68c7f57de3d6e584e88cfea4b21e82c9b64d3f08495c4f1f1e874bed"},"integrity":{"algorithm":"sha256","contentSha256":"6dd905b19fad54ce213b224f5e07e46876351e711b2d9ac0199b39c07aa9a463"}},"pubmed-pmid-42811017-motixafortide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-42811017-motixafortide:v1","objectPathId":"pubmed-pmid-42811017-motixafortide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-42811017-motixafortide/","json":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42811017-motixafortide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-42811017-motixafortide-v1"},"story":{"slug":"pubmed-pmid-42811017-motixafortide","version":1,"domain":"Literature metadata","dateInSource":"2026-11-09","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["motixafortide"],"peptides":[{"slug":"motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"}]},"claims":[{"id":"headline","text":"Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.","sourceIds":["pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996"]},{"id":"summary","text":"PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996"]},{"id":"paragraph-1","text":"PubMed lists PMID 42811017 in Nature communications as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996"]}],"sources":[{"id":"pubmed-observation-pmid-42811017-2026-11-09-09de67b6a996","name":"PubMed","sourceClass":"A","title":"Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives. · retained source version 1:2026-11-09:current:09de67b6a9967635985784a3306de9f6908e8de9ba91b253ccc9fbb373ed3264","url":"https://pubmed.ncbi.nlm.nih.gov/42811017/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7dd7526138de08c13e385ea70be682ccedcf00566ba9bf049d63de6ebba969c6","tierARecordSha256":"0b136d4464b837d0e8eaf63e42c02cce507178528bf082900411979e5d53bd14"},"integrity":{"algorithm":"sha256","contentSha256":"61733ba3a1de23184edbf8799c8333842b1e66fc871734801148eefdc2f3d508"}}}}
